Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 285 entries
View as:

Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05154630 Org: User:
Start: 01/14/22 End: 06/30/23 Due: 06/30/24

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Phase: N/A Priority: Normal
NCT ID: NCT04615468 Org: User:
Start: 12/01/20 End: 10/31/22 Due: 10/31/23

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Phase: N/A Priority: Normal
NCT ID: NCT05559242 Org: User:
Start: 10/31/22 End: 07/31/23 Due: 07/31/24

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Phase: N/A Priority: Normal
NCT ID: NCT06300320 Org: User:
Start: 05/07/24 End: 04/30/26 Due: 04/30/27

Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

Phase: N/A Priority: Normal
NCT ID: NCT06010537 Org: User:
Start: 04/28/21 End: 04/30/21 Due: 04/30/22

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT06644417 Org: User:
Start: 11/14/24 End: 08/31/26 Due: 08/31/27

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04073537 Org: User:
Start: 10/31/19 End: 06/30/22 Due: 06/30/23

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT06150014 Org: User:
Start: 12/07/23 End: 09/30/26 Due: 09/30/27

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06165809 Org: User:
Start: 12/31/23 End: 05/31/24 Due: 05/31/25

A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

Phase: N/A Priority: Normal
NCT ID: NCT06198764 Org: User:
Start: 07/06/23 End: 03/31/26 Due: 03/31/27

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05849727 Org: User:
Start: 08/30/23 End: 01/15/25 Due: 01/15/26

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase: N/A Priority: Normal
NCT ID: NCT02586350 Org: User:
Start: 07/31/15 End: 09/30/18 Due: 09/30/19

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05645315 Org: User:
Start: 04/28/22 End: 06/30/24 Due: 06/30/25

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04325763 Org: User:
Start: 05/27/20 End: 03/31/25 Due: 03/31/26

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04056754 Org: User:
Start: 07/16/14 End: 07/16/19 Due: 07/16/20

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Phase: N/A Priority: Normal
NCT ID: NCT05975645 Org: User:
Start: 08/15/23 End: 04/30/25 Due: 04/30/26

A Bioequivalence Study of Dasatinib Tablet

Phase: N/A Priority: Normal
NCT ID: NCT05640804 Org: User:
Start: 09/09/18 End: 10/08/19 Due: 10/08/20

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

Phase: N/A Priority: Normal
NCT ID: NCT02734966 Org: User:
Start: 12/31/07 End: 12/31/11 Due: 12/31/12

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05718167 Org: User:
Start: 02/28/23 End: 10/31/25 Due: 10/31/26

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Phase: N/A Priority: Normal
NCT ID: NCT06388759 Org: User:
Start: 08/01/22 End: 12/31/24 Due: 12/31/25

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT06859931 Org: User:
Start: 03/31/25 End: 12/31/26 Due: 12/31/27

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04924192 Org: User:
Start: 08/18/21 End: 12/30/23 Due: 12/30/24

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

Phase: N/A Priority: Normal
NCT ID: NCT02388919 Org: User:
Start: 02/26/15 End: 01/06/17 Due: 01/06/18

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)

Phase: N/A Priority: Normal
NCT ID: NCT02332499 Org: User:
Start: 12/31/14 End: 03/01/19 Due: 03/01/20

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT02944864 Org: User:
Start: 09/13/17 End: 09/15/22 Due: 09/15/23